🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

There are over 200 registrations (both virtual and on-site). We look forward to seeing you!

Can’t wait for the afternoon session to start for the #ilcaschool in Hong Kong Stephen L. Chan CUHK Medicine ILCA

ILCA cross over with APPlE!

Hot off the press! 🔥 Findings of the CARES-310 now out in The Lancet with our very own Prof Stephen L. Chan CUHK Medicine as co-first author sciencedirect.com/science/articl…

We are delighted to announce the publication of the first issue of ESMO Gastrointestinal Oncology Prof. Irit Ben-Aharon @FlorianLordick share their vision for this important new journal from ESMO - Eur. Oncology spkl.io/60144WYIy

How to improve quality of life #QOL of patients with #pancreatic cancer: jaundice, pain and ascites management, nutrition, exercise, radiotherapy #ESMO23 Stephen L. Chan Radka Obermannova Laura Dawson ESMO - Eur. Oncology

Ready for the #ESMO23 hepatobiliary session? Immunotherapy and molecularly targeted agents for #HCC and #CCA Angela Lamarca Jeroen Dekervel Arndt Vogel Stephen L. Chan ESMO - Eur. Oncology

Arndt Vogel presenting and discussing #immunotherapy for patients with advanced #HCC at #ESMO23 Angela Lamarca Jeroen Dekervel Stephen L. Chan ESMO - Eur. Oncology

Stephen L. Chan addressing the challenging topic of personalized treatment for patients with #HCC at #ESMO23 Angela Lamarca Jeroen Dekervel Arndt Vogel ESMO - Eur. Oncology

Huge THANK YOU to all speakers Lorenza Rimassa Arndt Vogel Stephen L. Chan and my co-chair Jeroen Dekervel for your expertise in this session today. We hopefully leave #ESMO23 convinced that #biopsies are the way forward to bring #PrecisionMedicine to #HCC 😉🧬 ESMO - Eur. Oncology

My dearest friend Molly Li suggested to me to start using X Happy to share this mini-review on the inaugural issue of ESMO gastrointestinal oncology on our views on neoadjuvant immunotherapy for HCC! Stephen L. Chan Janet Kung sciencedirect.com/science/articl…

Great discussion at the session on early drug development in GI cancers #ESMOAsia23 ESMO - Eur. Oncology Stephen L. Chan CUHK Medicine

Excellent talks on unresolved issues and future directions on BTC/HCC/GEC/GC in ESMO ASIA 2023! Stephen L. Chan Lizzy Smyth Dr. Do-Youn Oh

The strong #HongKong 🇭🇰 contingent in #ESMOAsia23 ! Tony Mok Molly Li Aya Helali MD PhD

Happy to share my *first* poster in international conference on the recurrence pattern of HCC following curative surgery and RFA in the era of effective antivirals! Thx for the support! Stephen L. Chan Molly Li Tony Mok

In the QS Ranking by Subject 2024 QS World University Rankings, CUHK Medicine is ranked 1st in #HongKong, 2nd in #Asia and 28th globally this year, while our Nursing School The Nethersole School of Nursing, CUHK is the top spot both in #HongKong and #Asia and holds the 8th position globally. Details (Medicine):

Stellar ⭐️ panel at ESMO - Eur. Oncology GI 2024 Lorenza Rimassa Stephen L. Chan Maria Reig discussing management of #HCC 💪

We are thrilled to announce Prof. Vlad Ratziu as the new Editor-in-Chief of Journal of Hepatology, starting January 2025! Joining him: ➡️Deputy Editors: Annalisa Berzigotti & Frank Tacke ➡️Co-Editors: Tom H. Karlsen, Lorenza Rimassa, & Heiner Wedemeyer ➡️Senior Editor: Philip Newsome EASLnews

Congratulations to the new #ilca #presidentelect Stephen L. Chan 👏👏👏

The FDA has issued a second rejection for the approval of rivoceranib plus camrelizumab as a first-line treatment for unresectable HCC. Here is the updated tracker of upcoming PDUFA dates and latest FDA approvals in oncology! Access real-time market intelligence and latest